0.36
+0.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About EyePoint
From its filings with the US Securities and Exchange Commission
EyePoint is based in Watertown, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EYPT. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $31.4m and a net loss of $232.0m. At that date it held total assets of $364.0m and shareholders' equity of $306.1m. By business, Product Rights Agreement [Member] brought in 50.7% of revenue, followed by RPA [Member] at 40.5% and YUTIQ [Member] at 5.1%. By region, Country US [Member] accounted for 95.6%, followed by China [Member] at 4.1% and UNITED KINGDOM [Member] at 0.3%.
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology (Durasert E) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E drug delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) and in Phase 3 clinical trials (COMO and CAPRI) for diabetic macular edema (DME). Additional pipeline programs include EYP-2301, razuprotafib, a TIE-2 agonist, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EyePoint is headquartered in Watertown, Massachusetts with a commercial manufacturing facility in Northbridge, Massachusetts.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jan 2005
- Employees
- 214
- Website
- eyepointpharma.com ↗
- Head office
- 480 PLEASANT STREET, WATERTOWN, MA, 02472
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Goeran AndoNon-Executive Independent Chairman of the Board$476,429
- Dr. Jay DukerPresident, Chief Executive Officer, Director, since 2016$6.0m
- Ms. Nancy LurkerExecutive Vice Chairman of the Board, since 2016$2.1m
- Mr. George ElstonChief Financial Officer, Executive Vice President$3.2m
- Mr. Ramiro RibeiroChief Medical Officer$3.5m
- Ms. Wendy DiciccoNon-Executive Independent Director$475,192
- Mr. Stuart DutyNon-Executive Independent Director$455,138
- Mr. Fred HassanNon-Executive Independent Director$408,717
- Dr. John LandisNon-Executive Independent Director$1.4m
- Dr. Reginald SandersNon-Executive Independent Director
- Ms. Karen ZaderejNon-Executive Independent Director$457,583
- Mr. Stern ..Investor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 6
- Social
- 94
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EyePoint Pharmaceuticals Inc has a strong portfolio of innovative eye care products.
- The company has a robust research and development pipeline with potential for future growth and expansion.
- EyePoint Pharmaceuticals Inc has a highly experienced and talented team of scientists and researchers.
- The company has established strong relationships with key stakeholders, including healthcare professionals and regulatory authorities.
Weaknesses
- EyePoint Pharmaceuticals Inc faces intense competition from other players in the eye care industry.
- The company's dependence on a few key products for revenue generation increases its vulnerability to market fluctuations.
- EyePoint Pharmaceuticals Inc may face challenges in effectively marketing and promoting its products to target customers.
- The company's financial performance has been inconsistent in recent years.
Opportunities
- Growing elderly population and increasing prevalence of eye-related diseases present a significant market opportunity for EyePoint Pharmaceuticals Inc.
- The company can explore partnerships and collaborations to expand its global reach and enter new markets.
- Advancements in technology and drug delivery systems offer opportunities for the development of innovative eye care solutions.
- EyePoint Pharmaceuticals Inc can leverage its strong R&D capabilities to develop differentiated products and gain a competitive advantage.
Threats
- Stringent regulatory requirements and approval processes pose a threat to the timely launch of new products.
- Rapidly changing market dynamics and evolving customer preferences can impact the demand for EyePoint Pharmaceuticals Inc's products.
- The company may face legal and intellectual property challenges from competitors.
- Fluctuating raw material prices can influence the company's production costs and profit margins.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.